Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Drugs in Dermatology

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5167/UZH-160510PMID 30124722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Successful Treatment of Post‐Transplant Generalized Pustular Psoriasis With Apremilast

  2025cites this paper
• Orismilast, a Potent and Selective PDE4B/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis

  2025cites this paper
• Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life

  2025cites this paper
• The role of cyclic adenosine monophosphate (cAMP) in pathophysiology of fibrosis.

  2025cites this paper
• Epac1 contributes to apremilast-mediated rescue of pemphigus autoantibody-induced loss of keratinocyte adhesion

  2025cites this paper
• Exploiting Marine Phospholipid Nanoliposomes for Enhanced Apremilast Delivery and Therapeutic Efficacy in Inflammatory Bowel Disease

  2025cites this paper
• Development and Optimization of Roflumilast-loaded Nanostructured Lipid Carrier (NLCs) Formulation for Topical Delivery

  2025cites this paper
• Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs

  2025cites this paper
• Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis.

  2025cites this paper
• Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.

  2025cites this paper
• Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients

  2024cites this paper
• Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study

  2024cites this paper
• Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats

  2024cites this paper
• Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study

  2023influential citation
• Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)

  2023cites this paper
• Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin.

  2023cites this paper
• Phosphodiesterase 4 D (PDE4D) gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis

  2023cites this paper
• Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis

  2023cites this paper
• cAMP: A master regulator of cadherin‐mediated binding in endothelium, epithelium and myocardium

  2023cites this paper
• Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer's-like pathology and symptoms through multiple targeting actions in aged T2D rats.

  2023cites this paper
• Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus

  2023cites this paper
• Apremilast prevents blistering in human epidermis by stabilization of keratinocyte adhesion in pemphigus

  2022cites this paper
• An update on emerging immunological targets and their inhibitors in the treatment of psoriasis.

  2022cites this paper
• Current emerging and investigational drugs for the treatment of chronic hand eczema

  2022cites this paper
• Rapid improvement of idiopathic aphthous ulcers with oral roflumilast therapy

  2022cites this paper
• Effects of Apremilast on Induced Hypertrophic Scar of Rabbits

  2022cites this paper
• Clinical Implication of Phosphodiesterase-4-Inhibition

  2022influential citation
• Preventive effect of levodopa on vitiligo development: a nationwide case–control study

  2022cites this paper
• PTT_A_303634 21..29

  2021cites this paper
• Phosphodiesterase-4 Inhibition in Psoriasis

  2021cites this paper
• Beneficial Impact of Apremilast on Palmoplantar Keratodermas

  2021cites this paper
• The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis

  2021cites this paper
• Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience

  2021cites this paper
• Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics

  2021cites this paper
• Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients

  2021cites this paper
• Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis

  2021cites this paper
• The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway

  2021cites this paper
• Effects of Apremilast on Induced Hypertrophic Scar of Rabbits.

  2021cites this paper
• An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 Mutation Enhancing Binding to NEK7

  2021cites this paper
• Common Fundamentals of Psoriasis and Depression

  2021cites this paper
• Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics for the treatment of psoriasis

  2021cites this paper
• CCID_A_320098 845..854

  2021cites this paper
• Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation

  2020influential citation
• Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review

  2020cites this paper
• The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients

  2020cites this paper
• Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

  2020cites this paper
• Vitiligo, From Physiopathology to Emerging Treatments: A Review

  2020cites this paper
• Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial

  2020cites this paper
• Treatment of Juvenile Spondyloarthritis: Where We Stand

  2020cites this paper
• Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis

  2020cites this paper
• Trial of Roflumilast Cream for Chronic Plaque Psoriasis.

  2020cites this paper
• Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.

  2020cites this paper
• Apremilast for psoriasis treatment.

  2020cites this paper
• Real‐world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group

  2020cites this paper
• The PDE4 inhibitor CHF6001 affects keratinocyte proliferation via cellular redox pathways.

  2020cites this paper
• Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers

  2020cites this paper
• Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases

  2019cites this paper
• Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis

  2019cites this paper
• Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects

  2019cites this paper
• Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report.

  2019cites this paper
• Inflammation of the Skin and Its Therapeutic Targets

  2019cites this paper
• The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis

  2019cites this paper
• Phosphodiesterase Type 4 Inhibition in CNS Diseases.

  2019cites this paper
• Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.

  2019cites this paper
• Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial.

  2019cites this paper
• Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

  2019cites this paper
• Cross Trial Meta and Time Series Pharmacodynamic Analyses of Apremilast Effects

  2019cites this paper
• Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis

  2019cites this paper
• A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata

  2018cites this paper